Early eptinezumab responders continue to experience strong reductions in monthly migraine days across 72 weeks, with sustained response being more frequent at the higher dose.
Medscape News UK
Source link : https://www.medscape.com/viewarticle/eptinezumab-sustains-long-term-migraine-response-2026a10008r8?src=rss
Author :
Publish date : 2026-03-25 12:00:00
Copyright for syndicated content belongs to the linked Source.